Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
29 hedge funds and large institutions have $3.07M invested in Biolase, Inc. in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 8 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
117% more capital invested
Capital invested by funds: $1.42M → $3.07M (+$1.65M)
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
12% more funds holding
Funds holding: 26 → 29 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$170K |
| 2 |
Squarepoint
New York
|
+$157K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$156K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$139K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$59.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$82.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$49K |
| 3 |
VF
Virtu Financial
New York
|
-$38.9K |
| 4 |
Jane Street
New York
|
-$15K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$13.7K |
BIOL Hedge Fund Activity: Q4 2020 in Review
29 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q4 2020, worth a combined $3.07M — up 117% from $1.42M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BIOL positions and 8 closed out — a net gain of 4 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Invenomic Capital Management, adding an estimated $170K. The largest seller was Sabby Management, cutting an estimated $82.4K.
- 29 institutional investors held Biolase, Inc. (BIOL) as of Q4 2020, up from 26 in Q3 2020.
- Funds reported $3.07M of Biolase, Inc. stock for Q4 2020, up 117% quarter-over-quarter.
- 12 funds opened new Biolase, Inc. positions in Q4 2020 and 8 closed out, a net change of +4 holders.
- The largest Biolase, Inc. buyer in Q4 2020 was Invenomic Capital Management, an estimated $170K added.
- The largest Biolase, Inc. seller in Q4 2020 was Sabby Management, an estimated $82.4K sold.
Based on aggregated 13F filings for Q4 2020.